The stock of Lipocine Inc (NASDAQ:LPCN) is a huge mover today! About 397,721 shares traded hands or 73.11% up from the average. Lipocine Inc (NASDAQ:LPCN) has declined 62.75% since February 26, 2016 and is downtrending. It has underperformed by 73.18% the S&P500.
The move comes after 8 months positive chart setup for the $75.48 million company. It was reported on Sep, 30 by Barchart.com. We have $8.17 PT which if reached, will make NASDAQ:LPCN worth $61.89M more.
Analysts await Lipocine Inc (NASDAQ:LPCN) to report earnings on November, 10. They expect $-0.31 earnings per share, up 11.43% or $0.04 from last year’s $-0.35 per share. After $-0.32 actual earnings per share reported by Lipocine Inc for the previous quarter, Wall Street now forecasts -3.13% EPS growth.
Lipocine Inc (NASDAQ:LPCN) Ratings Coverage
Out of 3 analysts covering Lipocine Inc (NASDAQ:LPCN), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Lipocine Inc has been the topic of 3 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The company was initiated on Wednesday, July 22 by TH Capital. Empire maintained the shares of LPCN in a report on Wednesday, August 12 with “Buy” rating. Roth Capital initiated Lipocine Inc (NASDAQ:LPCN) on Wednesday, July 22 with “Buy” rating.
According to Zacks Investment Research, “Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men’s and women’s health. The Company’s lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, indicated for the prevention of preterm birth and is currently in Phase 1. Lipocine Inc. is headquartered in Salt Lake City, Utah.”
More important recent Lipocine Inc (NASDAQ:LPCN) news were published by: Streetinsider.com which released: “Form 8-K Lipocine Inc. For: Sep 26” on September 26, 2016, also Globenewswire.com published article titled: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Lipocine Inc …”, Seekingalpha.com published: “Lipocine Vs. Antares: Who Wins?” on April 20, 2016. More interesting news about Lipocine Inc (NASDAQ:LPCN) was released by: Globenewswire.com and their article: “Lawsuit for Investors in shares of Lipocine Inc (NASDAQ:LPCN) announced by …” with publication date: July 25, 2016.
LPCN Company Profile
Lipocine Inc., incorporated on October 13, 2011, is a specialty pharmaceutical company. The Firm is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The Company’s primary development programs are based on oral delivery solutions for bioavailable drugs. The Firm has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitates lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminates gastrointestinal interactions that limit bioavailability. The Company’s lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.